Evidence map›Paper›PMID 38863976›Full record

ArticleFrontiers in pharmacology2024

Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.

Chun-Li Lu, Liu-Qing Yang, Xin-Yan Jin, Thomas Friedemann, Yu-Fei Li, Xue-Han Liu, Xiao-Ying Chen, Xiang-Yun Zou, Bing-Rui Zhang, Fu-Xiang Wang and 11 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chun-Li Lu *Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Liu-Qing Yang *The Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.
Xin-Yan JinCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Thomas FriedemannHanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg, Germany.
Yu-Fei LiCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xue-Han LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xiao-Ying ChenCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xiang-Yun ZouCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Bing-Rui ZhangCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Fu-Xiang WangThe Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.
Yuan-Long LinThe Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.
Yi-Min TangThe Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.
Meng-Li CaoThe Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.
Ya-Lin JiangThe People's Hospital of Bozhou, Bozhou, China.
You-Fang GaoThe People's Hospital of Bozhou, Bozhou, China.
Kui LiuThe People's Hospital of Bozhou, Bozhou, China.
Zhen-Gang TaoZhongshan Hospital Affiliated of Fudan University, Shanghai, China.
Nicola RobinsonCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Sven SchröderHanseMerkur Center for Traditional Chinese Medicine at the University Medical Center, Hamburg, Germany.
Jian-Ping Liu *Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Hong-Zhou Lu *The Third People's Hospital of Shenzhen, The Second Affiliated Hospital to Southern University of Science and Technology, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chinese herbal medicineCOVID-19randomized control trialShufeng Jiedu capsulessymptom relief

Identifiers

PMID38863976
PMCPMC11165997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.